ClinicalTrials.gg
CompletedNCT00540423Updated Mar 30, 2011Results posted

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Phase 3 interventional study of SB-497115-GR 12.5mg and SB-497115-GR 25mg in Chronic Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-03-30.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
27th of 36
23 · median 40
Started
2007
with 2 others
Phase 3
9 of 36
none open now
Registered
6th of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 27th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 6th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients

03

Conditions studied

  • Chronic Idiopathic Thrombocytopenic Purpura
  • Purpura, Thrombocytopenic, Idiopathic

Keywords

  • thrombopoietin,
  • immunosuppressive therapy,
  • eltrombopag,
  • idiopathic thrombocytopenic purpura,
  • blood platelet,
  • splenectomy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following criteria.

At Screening (Week -4 or -3)

  • Diagnosed with ITP for at least 6 months prior to screening.
  • Have a count of \<30,000/µL.
  • Previously treated or relapsed patients who have failed to achieve a platelet count of >=30,000/µL despite one or more prior therapies (either H. pylori eradication, , splenectomy, danazol or drugs). (Note: Previous H. pylori eradication must have been completed at least 3 months prior to screening and clearly be ineffective).
  • Previous treatment for ITP with splenectomy, rituximab, and cyclophosphamide must have been completed at Week -4 and clearly be ineffective.
  • Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to screening."
  • A complete blood count (CBC) within the reference range, with the following exceptions

    1. : females >=9g/dL and males >=10g/dL are eligible for inclusion if hemorrhage is present.
    2. >=1,500/µL (1.5x109/L) is required for inclusion.
  • The following clinical chemistries MUST NOT exceed 1.2 times the normal reference range:creatinine, , AST, total and alkaline phosphatase.
  • Albumin must be within 80 to 120% of normal range.
  • Subject is >=20 years old.
  • Female subjects must either be:
  • of non- (bilateral tubal ligation or ), or
  • of childbearing potential and have a negative pregnancy test and agree to use methods specified in the GSK List of Highly Effective Methods for Avoidance of Pregnancy
  • Hospitalization status: No restriction.
  • Gender: No restriction.
  • Subject has signed and dated written . At Randomization (Week 0)
  • Have a platelet count of \<30,000/µL.
  • Previous therapy for ITP with immunoglobulins (IVIG and anti-D) and vincristine must have been completed at least 2 weeks prior to randomization and the platelet count must show a clear downward trend after the last treatment with immunoglobulins.
  • Subjects treated with corticosteroids or azathioprine must be receiving a dose that has been stable for at least 4 weeks prior to randomization.
  • Prolongation of and activated partial thromboplastin time (aPTT) must not exceed 1.2 times the with no history of hypercoagulable state. (Note: These parameters will be measured at screening or at randomization.)
  • CBC and clinical chemistries fulfill the same criteria as those at screening.
  • Reticulocyte count within the reference range or elevated in case of bleeding. (Note: This parameter will be measured at screening or at randomization.)

Exclusion criteria

Exclusion criteria:

Subjects meeting any of the following criteria must not be enrolled in the study.

At Screening (Week -4 or -3)

  • Any severe medical condition (cardiac, hepatic or renal disorder) other than chronic ITP. (Note: ""Severe"" is defined as >=Grade 3 as a rule according to the ""Classification of the Severity of Adverse Experiences (PAB/SD Notification No.80, dated 29 June 1992) (Appendix X).)
  • History of suspected or confirmed arterial or venous thrombosis (e.g., myocardial infarction, deep vein thrombosis) within the last 1 year.
  • History of drug/alcohol abuse or dependence within 1 year prior to screening.
  • Previous treatment with SB-497115-GR.
  • Suspected blood disorder other than ITP.
  • Suspected aggregation abnormality.
  • Suspected cyclic thrombocytopenia
  • Current or history of infection or virus or virus infections.
  • Current or history of (Exception: Subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).
  • Female subjects who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
  • Subjects who are deemed unsuitable for the study by the investigator (or sub investigator).
  • Subjects who are participating in any other clinical trials at present or ones who previously participated in clinical trials and were treated with products within last one month." At Randomization (Week 0)
  • Subject wishes to withdraw consent.
  • Subject is lost to follow-up.
  • Subject has consumed anti-platelet agents (e.g., ticlopidine and aspirin), anticoagulants, or non-steroidal anti-inflammatory drugs (NSAIDs) for 7days prior to the first dose of study medication and will require these medications during the study period.
  • Subjects who are deemed unsuitable for the study by the investigator (or sub investigator).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    SB-497115-GR group

    Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.

    Drug: SB-497115-GR 12.5mg · Drug: SB-497115-GR 25mg · Drug: SB-497115-GR 50 mg

  • Placebo comparator
    placebo group

    Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.

    Drug: SB-497115-GR 12.5mg matching placebo

Interventions

  • SB-497115-GR 12.5mg tablet once a day

  • SB-497115-GR 25mg tablet once a day

  • DrugSB-497115-GR 12.5mg matching placebo

    SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day

  • SB-497115-GR 25mg tablet x2 once a day

    Also known as: SB-497115-GR 50mg

06

What researchers measure

Primary outcomes

  1. Number of Responders at Week 6

    A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).

    Time frame: Week 6

  2. Percentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders

    A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Week 26

Secondary outcomes

  1. Number of Participants Assessed as Responders in at Least 4 Assessments Between Weeks 2 and 6

    A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter) at at least 4 out of 5 scheduled visits.

    Time frame: Weeks 2 through 6

  2. Percentage of Responders at Each Visit

    A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).

    Time frame: Days 8, 15, 22, 29, 36, and 43

  3. Mean Platelet Count at Each Visit

    Blood taken from peripheral blood vessels was used for the measurement of platelet counts.

    Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43

  4. Mean Change From Baseline in Platelet Counts at Each Visit

    Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 minus baseline value

    Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43

  5. Percentage of Participants With Bleeding Episodes Since the Last Visit

    When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s).

    Time frame: Days 1, 8, 15, 22, 29, 36, and 43

  6. Number of Participants at Baseline and Days 8, 15, 22, 29, 36, and 43 of Treatment by Platelet Count Category

    Blood taken from peripheral blood vessels was used for the measurement of platelet counts.

    Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43

  7. Percentage of Responders at Each Visit

    A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26

  8. Mean Platelet Counts of Participants at Each Visit

    Blood taken from peripheral blood vessels was used for the measurement of platelet counts. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26

  9. Mean Change From Baseline in Platelet Counts at Each Visit

    Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 and Weeks 10, 14, 18, 22, and 26 minus baseline value. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26

  10. Mean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter

    Maximum duration is measured as the longest period (days) for which a participant continuously maintained platelet counts within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Weeks 1 through 26

  11. Mean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter

    Total time is measured as the cumulative number of days over which platelet counts were maintained within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Weeks 1 through 26

  12. Percentage of Participants With Bleeding Episode Since the Last Visit

    When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Days 1, 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26

  13. Percentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline

    ITP medications are drugs, such as steroids or immunoglobulin, to be used for ITP. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Baseline through Week 26

  14. Percentage of Participants Who Received Rescue Treatment for ITP

    Rescue treatment for ITP is treatment applied to participants at high bleeding risk, such as those undergoing platelet transfusion or dose increase of steroids. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Weeks 1 through 26

  15. Mean Number of Days of Concomitant ITP Medication Use Per Month

    Cumulative number of days for which a participant received ITP medication during the treatment/total treatment period (months). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

    Time frame: Weeks 1 through 26

  16. Pharmacokinetics of SB-497115-GR, Cmax

    Cmax: Peak plasma concentration of SB-497115

    Time frame: Week 9 or 10

  17. Pharmacokinetics of SB-497115-GR, Tmax

    tmax: Time when Cmax was achieved

    Time frame: Week 9 or 10

  18. Pharmacokinetics of SB-497115, t1/2

    t1/2 is half life based on the terminal phase

    Time frame: Week 9 or 10

  19. Pharmacokinetics of SB-497115-GR, Lambda z

    Lambda z is first order rate constant associated with the terminal portion of the plasma concentration curve.

    Time frame: Week 9 or 10

  20. Pharmacokinetics of SB-497115-GR, AUClast and AUC0-24

    AUC is area under a concentration vs. time curve. AUC0-24 (Area under the plasma concentration-time curve between 0 to 24 hrs) is calculated using the following equation: AUC0-24= AUClast + Clast × (1 - e-λz × \[24-tlast\])/λz. AUClast is AUC (area under a curve) computed to the last observation. Clast is concentration of last observation.

    Time frame: Week 9 or 10

  21. Pharmacokinetics of SB-497115-GR, CL/F

    CL/F: CL is an estimate of the total body clearance, and F is the fraction of dose absorbed.

    Time frame: Week 9 or 10

  22. Pharmacokinetics of SB-497115-GR, Vz/F

    VZ/F: VZ is the volume of distribution based on the terminal phase, and F is the fraction of dose absorbed.

    Time frame: Week 9 or 10

07

Results

Posted Dec 31, 2009

Participant flow

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestonePlaceboSB-497115-GR, Double-blindSB-497115-GR, Open-label
Started8150
Completed8140
Not completed010
Withdrew: Adverse event010
Open-Label Treatment Period
Participant flow — Open-Label Treatment Period
MilestonePlaceboSB-497115-GR, Double-blindSB-497115-GR, Open-label
Started0022
Completed0020
Not completed002
Withdrew: Lack of efficacy002

Outcome measures

PrimaryNumber of Responders at Week 6

A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).

Time frame:
Week 6
Reported as:
Number · Participants
Number of Responders at Week 6
ParticipantsSB-497115-GRPlacebo
Responders90
Non-responders68
Statistical analysis
  • SB-497115-GR vs Placebo · Risk difference (rd): 60 · 95% CI 35.21 to 84.79The units of risk difference is percentage.
SecondaryNumber of Participants Assessed as Responders in at Least 4 Assessments Between Weeks 2 and 6

A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter) at at least 4 out of 5 scheduled visits.

Time frame:
Weeks 2 through 6
Reported as:
Number · Participants
Number of Participants Assessed as Responders in at Least 4 Assessments Between Weeks 2 and 6
ParticipantsSB-497115-GRPlacebo
Responders50
Non-responders98
PrimaryPercentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders

A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders
percentage of participantsSB-497115-GR
Percentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders43.5
Statistical analysis
  • SB-497115-GR · Percentage of 75% responders: 43.5 · 95% CI 23.19 to 65.51Confidence interval of the percentage of participants for whom at least 75% of their assessments during the course of 26 weeks of SB-494115-GR treatment met the definition of responders.
SecondaryPercentage of Responders at Each Visit

A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).

Time frame:
Days 8, 15, 22, 29, 36, and 43
Reported as:
Number · Percentage of responders
Percentage of Responders at Each Visit
Percentage of respondersSB-497115-GRPlacebo
Day 86.70
Day 1526.70
Day 2233.30
Day 2960.00
Day 3666.70
Day 4360.00
SecondaryMean Platelet Count at Each Visit

Blood taken from peripheral blood vessels was used for the measurement of platelet counts.

Time frame:
Baseline and Days 8, 15, 22, 29, 36, and 43
Reported as:
Mean · 10^9/Liter
Mean Platelet Count at Each Visit
10^9/LiterSB-497115-GRPlacebo
Baseline19.3 ± 6.7912.6 ± 8.65
Day 826.9 ± 17.7714.3 ± 12.26
Day 1554.9 ± 55.8413.5 ± 12.15
Day 2254.4 ± 46.8811.6 ± 9.50
Day 2973.3 ± 46.7210.6 ± 9.04
Day 3699.4 ± 78.6211.9 ± 10.79
Day 4395.1 ± 100.259.9 ± 4.76
SecondaryMean Change From Baseline in Platelet Counts at Each Visit

Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 minus baseline value

Time frame:
Baseline and Days 8, 15, 22, 29, 36, and 43
Reported as:
Mean · 10^9/Liter
Mean Change From Baseline in Platelet Counts at Each Visit
10^9/LiterPlaceboSG-497115-GR
Day 81.6 ± 6.057.6 ± 16.47
Day 150.9 ± 5.4635.5 ± 56.11
Day 22-1.0 ± 3.0235.0 ± 46.52
Day 29-2.0 ± 4.1753.9 ± 46.02
Day 36-0.8 ± 7.9480.1 ± 77.06
Day 43-2.8 ± 9.4175.8 ± 99.93
SecondaryPercentage of Participants With Bleeding Episodes Since the Last Visit

When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s).

Time frame:
Days 1, 8, 15, 22, 29, 36, and 43
Reported as:
Number · Percentage of participants
Percentage of Participants With Bleeding Episodes Since the Last Visit
Percentage of participantsSB-497115-GRPlacebo
Day 13375
Day 81363
Day 151463
Day 222975
Day 29038
Day 36763
Day 431475
SecondaryNumber of Participants at Baseline and Days 8, 15, 22, 29, 36, and 43 of Treatment by Platelet Count Category

Blood taken from peripheral blood vessels was used for the measurement of platelet counts.

Time frame:
Baseline and Days 8, 15, 22, 29, 36, and 43
Reported as:
Number · Participants
Number of Participants at Baseline and Days 8, 15, 22, 29, 36, and 43 of Treatment by Platelet Count Category
ParticipantsSB-497115-GRPlacebo
Baseline, Platelet counts (PC) <=15 x 10^9/L36
Baseline, PC >15 to <30 x 10^9/L122
Baseline, PC >=30 to <=50 x 10^9/L00
Baseline, PC =>50 to <=200 x 10^9/L00
Baseline, PC >200 to <=400 x 10^9/L00
Baseline, PC >400 x 10^9/L00
Day 8, PC <=15 x 10^9/L35
Day 8, PC >15 to <30 x 10^9/L62
Day 8, PC >=30 to <=50 x 10^9/L51
Day 8, PC =>50 to <=200 x 10^9/L10
Day 8, PC >200 to <=400 x 10^9/L00
Day 8, PC >400 x 10^9/L00
Day 15, PC <=15 x 10^9/L26
Day 15, PC >15 to <30 x 10^9/L31
Day 15, PC >=30 to <=50 x 10^9/L51
Day 15, PC =>50 to <=200 x 10^9/L30
Day 15, PC >200 to <=400 x 10^9/L10
Day 15, PC >400 x 10^9/L00
Day 22, PC <=15 x 10^9/L35
Day 22, PC >15 to <30 x 10^9/L33
Day 22, PC >=30 to <=50 x 10^9/L30
Day 22, PC =>50 to <=200 x 10^9/L50
Day 22, PC >200 to <=400 x 10^9/L00
Day 22, PC >400 x 10^9/L00
Day 29, PC <=15 x 10^9/L16
Day 29, PC >15 to <30 x 10^9/L02
Day 29, PC >=30 to <=50 x 10^9/L40
Day 29, PC =>50 to <=200 x 10^9/L90
Day 29, PC >200 to <=400 x 10^9/L00
Day 29, PC >400 x 10^9/L00
Day 36, PC <=15 x 10^9/L27
Day 36, PC >15 to <30 x 10^9/L00
Day 36, PC >=30 to <=50 x 10^9/L21
Day 36, PC =>50 to <=200 x 10^9/L90
Day 36, PC >200 to <=400 x 10^9/L10
Day 36, PC >400 x 10^9/L00
Day 43, PC <=15 x 10^9/L27
Day 43, PC >15 to <30 x 10^9/L21
Day 43, PC >=30 to <=50 x 10^9/L10
Day 43, PC =>50 to <=200 x 10^9/L70
Day 43, PC >200 to <=400 x 10^9/L20
Day 43, PC >400 x 10^9/L00
SecondaryPercentage of Responders at Each Visit

A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Reported as:
Number · Percentage of responders
Percentage of Responders at Each Visit
Percentage of respondersSB-497115-GR
Day 84.3
Day 1517.4
Day 2221.7
Day 2947.8
Day 3656.5
Day 4352.2
Week 1057.1
Week 1460.9
Week 1850.0
Week 2252.4
Week 2669.6
SecondaryMean Platelet Counts of Participants at Each Visit

Blood taken from peripheral blood vessels was used for the measurement of platelet counts. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Reported as:
Mean · 10^9/Liter
Mean Platelet Counts of Participants at Each Visit
10^9/LiterSB-497115-GR
Baseline16.5 ± 8.45
Day 823.0 ± 16.77
Day 1541.5 ± 48.32
Day 2241.0 ± 41.80
Day 2955.3 ± 45.75
Day 3678.1 ± 72.76
Day 4378.0 ± 88.31
Week 1088.9 ± 81.15
Week 14121.6 ± 121.20
Week 1887.3 ± 80.09
Week 2278.5 ± 57.58
Week 2686.2 ± 49.62
SecondaryMean Change From Baseline in Platelet Counts at Each Visit

Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 and Weeks 10, 14, 18, 22, and 26 minus baseline value. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Reported as:
Mean · 10^9/Liter
Mean Change From Baseline in Platelet Counts at Each Visit
10^9/LiterSB-497115-GR
Day 86.4 ± 13.53
Day 1525.1 ± 46.73
Day 2224.6 ± 39.37
Day 2938.9 ± 42.37
Day 3661.7 ± 69.53
Day 4361.6 ± 86.72
Week 1071.4 ± 80.01
Week 14104.5 ± 120.20
Week 1869.4 ± 80.23
Week 2261.1 ± 54.85
Week 2668.4 ± 46.49
SecondaryMean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter

Maximum duration is measured as the longest period (days) for which a participant continuously maintained platelet counts within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Weeks 1 through 26
Reported as:
Mean · Days
Mean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter
DaysSB-497115-GR
Mean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter59.5 ± 46.99
SecondaryMean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter

Total time is measured as the cumulative number of days over which platelet counts were maintained within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Weeks 1 through 26
Reported as:
Mean · Days
Mean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter
DaysSB-497115-GR
Mean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter78.4 ± 54.56
SecondaryPercentage of Participants With Bleeding Episode Since the Last Visit

When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Days 1, 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Bleeding Episode Since the Last Visit
Percentage of participantsSB-497115-GR
Day 148
Day 835
Day 1527
Day 2236
Day 2918
Day 3623
Day 4327
Week 1011
Week 1414
Week 1826
Week 2228
Week 265
SecondaryPercentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline

ITP medications are drugs, such as steroids or immunoglobulin, to be used for ITP. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Baseline through Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline
Percentage of participantsSB-497115-GR
Percentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline36.8
SecondaryPercentage of Participants Who Received Rescue Treatment for ITP

Rescue treatment for ITP is treatment applied to participants at high bleeding risk, such as those undergoing platelet transfusion or dose increase of steroids. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Weeks 1 through 26
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Rescue Treatment for ITP
Percentage of participantsSB-497115-GR
Percentage of Participants Who Received Rescue Treatment for ITP9
SecondaryMean Number of Days of Concomitant ITP Medication Use Per Month

Cumulative number of days for which a participant received ITP medication during the treatment/total treatment period (months). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.

Time frame:
Weeks 1 through 26
Reported as:
Mean · Days
Mean Number of Days of Concomitant ITP Medication Use Per Month
DaysSB-497115-GR
Mean Number of Days of Concomitant ITP Medication Use Per Month25.14 ± 11.796
SecondaryPharmacokinetics of SB-497115-GR, Cmax

Cmax: Peak plasma concentration of SB-497115

Time frame:
Week 9 or 10
Reported as:
Mean · ng/mL (nanograms/milliliter)
Pharmacokinetics of SB-497115-GR, Cmax
ng/mL (nanograms/milliliter)SB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115-GR, Cmax2992.4 ± 1253.146776.4 ± 2619.6211877.8 ± 3926.21
SecondaryPharmacokinetics of SB-497115-GR, Tmax

tmax: Time when Cmax was achieved

Time frame:
Week 9 or 10
Reported as:
Median · Hours
Pharmacokinetics of SB-497115-GR, Tmax
HoursSB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115-GR, Tmax3.192 (2.00 to 4.17)4.000 (2.00 to 4.00)2.967 (1.92 to 4.17)
SecondaryPharmacokinetics of SB-497115, t1/2

t1/2 is half life based on the terminal phase

Time frame:
Week 9 or 10
Reported as:
Mean · Hours
Pharmacokinetics of SB-497115, t1/2
HoursSB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115, t1/219.50 ± 7.16429.96 ± 7.66418.19 ± 4.938
SecondaryPharmacokinetics of SB-497115-GR, Lambda z

Lambda z is first order rate constant associated with the terminal portion of the plasma concentration curve.

Time frame:
Week 9 or 10
Reported as:
Mean · 1/hour
Pharmacokinetics of SB-497115-GR, Lambda z
1/hourSB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115-GR, Lambda z0.04021 ± 0.0155580.02724 ± 0.0068810.04040 ± 0.011422
SecondaryPharmacokinetics of SB-497115-GR, AUClast and AUC0-24

AUC is area under a concentration vs. time curve. AUC0-24 (Area under the plasma concentration-time curve between 0 to 24 hrs) is calculated using the following equation: AUC0-24= AUClast + Clast × (1 - e-λz × \[24-tlast\])/λz. AUClast is AUC (area under a curve) computed to the last observation. Clast is concentration of last observation.

Time frame:
Week 9 or 10
Reported as:
Mean · hr*ng/mL
Pharmacokinetics of SB-497115-GR, AUClast and AUC0-24
hr*ng/mLSB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
AUClast41671.5 ± 24344.6492556.2 ± 41095.63171523.2 ± 75250.93
AUC0-2441637.2 ± 24361.5192527.5 ± 41122.30171551.0 ± 75242.59
SecondaryPharmacokinetics of SB-497115-GR, CL/F

CL/F: CL is an estimate of the total body clearance, and F is the fraction of dose absorbed.

Time frame:
Week 9 or 10
Reported as:
Mean · L/hr (Liters/hour)
Pharmacokinetics of SB-497115-GR, CL/F
L/hr (Liters/hour)SB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115-GR, CL/F0.37156 ± 0.1542840.30923 ± 0.1140960.33035 ± 0.124401
SecondaryPharmacokinetics of SB-497115-GR, Vz/F

VZ/F: VZ is the volume of distribution based on the terminal phase, and F is the fraction of dose absorbed.

Time frame:
Week 9 or 10
Reported as:
Mean · Liters
Pharmacokinetics of SB-497115-GR, Vz/F
LitersSB-497115-GR 12.5 mgSB-497115-GR 25 mgSB-497115-GR 50 mg
Pharmacokinetics of SB-497115-GR, Vz/F5.6267 ± 2.009645.3870 ± 1.750775.0391 ± 1.76091

Adverse events

Collected over AE data were collected from the beginning of the double-blind (DB) phase. In the Long-Term (LT) phase, AEs were pooled from all participants (pts) who started the DB phase, regardless of whether they completed the phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Short-Term (Double-Blind) Phase—0/8 (0%)2/8 (25%)
SB-497115-GR Short-Term (Double-Blind) Phase—1/15 (6.7%)7/15 (46.7%)
SB-497115-GR Long-Term Phase—6/23 (26.1%)19/23 (82.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo Short-Term (Double-Blind) PhaseSB-497115-GR Short-Term (Double-Blind) PhaseSB-497115-GR Long-Term Phase
Hemorrhagic diathesisBlood and lymphatic system disorders0/80/152/23
Transient ischemic attackNervous system disorders0/81/151/23
ThrombocytopeniaBlood and lymphatic system disorders0/80/151/23
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/151/23
Renal impairmentRenal and urinary disorders0/80/151/23
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlacebo Short-Term (Double-Blind) PhaseSB-497115-GR Short-Term (Double-Blind) PhaseSB-497115-GR Long-Term Phase
NasopharyngitisInfections and infestations0/84/1510/23
Alanine aminotransferase increasedHepatobiliary disorders0/83/154/23
Aspartate aminotransferase increasedHepatobiliary disorders0/81/153/23
HeadacheNervous system disorders1/81/153/23
CataractEye disorders1/80/150/23
CystitisInfections and infestations0/80/152/23
GastroenteritisInfections and infestations0/81/152/23
Herpes simplexInfections and infestations0/80/152/23
RhinitisInfections and infestations0/80/152/23
NauseaGastrointestinal disorders0/81/152/23

Baseline characteristics

Age Continuous
Age Continuous(years)SB-497115-GRPlaceboTotal
Mean53.7 ± 13.7258.4 ± 11.7255.3 ± 12.98
Sex: Female, Male
Sex: Female, Male(Participants)SB-497115-GRPlaceboTotal
Female8715
Male718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SB-497115-GRPlaceboTotal
Japanese Heritage15823
08

Study locations

7 sites
  • GSK Investigational Site
    Gifu, 503-8502, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Ibaraki, 305-8576, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Osaka, 596-8501, Japan
  • GSK Investigational Site
    Tochigi, 329-0498, Japan
  • GSK Investigational Site
    Tokyo, 160-8582, Japan
09

References and documents

Publications

  • Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012 May;10(5):799-806. doi: 10.1111/j.1538-7836.2012.04695.x. PubMed 22409309 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2007
First posted
Oct 8, 2007
Start
Sep 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Dec 31, 2009
Last update
Mar 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00540423
Lead sponsor
GlaxoSmithKline
First posted
Oct 8, 2007
Start date
Sep 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Dec 31, 2009
Last update
Mar 30, 2011

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion